

Manuscript no. HAEMATOL/2012/069369 entitled “Clinical implications of the molecular genetics of chronic lymphocytic leukemia“

Authors: Robin Foà, Ilaria Del Giudice, Anna Guarini, Davide Rossi, Gianluca Gaidano

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:

Robin Foà, Division of Hematology, Department of Cellular Biotechnologies and Hematology, University "Sapienza", Rome, Italy. e-mail: rfoa@bce.uniroma1.it

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Robin Foà, Gianluca Gaidano, Anna Guarini designed and critically revised the manuscript

3) Design & Methods. The following authors were responsible for specific investigations:

- Ilaria Del Giudice reviewed the literature, being specifically responsible for the following parts of the review: Genetic heterogeneity of CLL; Molecular characteristics of clinically relevant genetic lesions of CLL (regarding TP53 and ATM); Clinical relevance of TP53 abnormalities in CLL; Clinical relevance of ATM abnormalities in CLL; Molecular genetics as a guide for choosing therapy.
- Davide Rossi reviewed the literature, being specifically responsible for the following parts of the review: Molecular lesions at different clinical phases of CLL; Clonal evolution of CLL; Clinical relevance of novel molecular lesions.
- Anna Guarini gave a substantial contribution to TP53 and ATM related topics.

4) Results. The following authors were responsible for specific portions of the results, including figures and tables:

- Ilaria Del Giudice reviewed the literature, being specifically responsible for the following parts of the review: Genetic heterogeneity of CLL; Molecular characteristics of clinically relevant genetic lesions of CLL (regarding TP53 and ATM); Clinical relevance of TP53 abnormalities in CLL; Clinical relevance of ATM abnormalities in CLL; Molecular genetics as a guide for choosing therapy
- Davide Rossi reviewed the literature, being specifically responsible for the following parts of the review: Molecular lesions at different clinical phases of CLL; Clonal evolution of

CLL; Clinical relevance of novel molecular lesions. He is also responsible for Table 1 and Figure 1 and 2

5) Writing the manuscript. The following authors were responsible for writing the manuscript:

Ilaria Del Giudice and Davide Rossi wrote the manuscript

6) Contributors Listed in Acknowledgments:

The work by the authors described in this review was supported by AIRC Special Program Molecular Clinical Oncology, 5 x 1000, No. 10007, Milan, Italy (to R.F. and to G.G.); Compagnia di San Paolo, Torino, Italy (R.F.); Progetto FIRB-Programma “Futuro in Ricerca” 2008 (to D.R.); PRIN 2008 (to G.G.) and 2009 (to D.R.), MIUR, Rome, Italy; Progetto Giovani Ricercatori 2008 (to D.R.), Ministero della Salute, Rome, Italy; and Novara-AIL Onlus, Novara (to G.G.), Italy